Cart (0 Items)
Your cart is currently empty.
View Products-
-
-
Romosozumab Biosimilar – Anti-SOST mAb – Research Grade
| Size | 100ug, 1MG |
|---|---|
| Isotype | IgG2, kappa |
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Clonality | Monoclonal Antibody |
| Expression system | Mammalian cells |
| Applications | Elisa, WB |
| Product name | Romosozumab Biosimilar - Anti-SOST mAb - Research Grade |
|---|---|
| Source | CAS 909395-70-6 |
| Species | Humanized |
| Molecular weight | 146kDa |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | Romosozumab,785A070802,AMG 785,CDP-7851,romosozumab-aqqg,sclerostin Ab,SOST,anti-SOST |
| Reference | PX-TA1281 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG2-kappa |
| Clonality | Monoclonal Antibody |
Description of Romosozumab Biosimilar - Anti-SOST mAb - Research Grade
General information on Anti-SOST[Homo sapiens] (Romosozumab) Monoclonal Antibody
Romosozumab is a humanized monoclonal antibody used for the treatment of osteoperosis.
SDS-PAGE for Romosozumab Biosimilar - Anti-SOST mAb
Romosozumab Biosimilar - Anti-SOST mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Immobilized Human SOST recombinant protein (cat. No.PX-P6275) at 0.5µg/mL (100µL/well) can bind to Romosozumab Biosimilar - Anti-SOST mAb (cat. No.PX-TA1281) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Related products
Antigen
Lysostaphin(lss)
PX-P4876 250$
Antigen
Sclerostin (SOST )
PX-P4621 217$
Isotype Control
Human IgG2 Isotype Control antibody (HyHEL-10)
PTX17900 215$
ELISA
Romosozumab ELISA Kit
KPTX275 1404$Contact us
Send us a message from the form below
Reviews
There are no reviews yet.